America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
In which types of cancer has AOH1996 shown promise during clinical trials according to Dr. Malkas?
**Interview with Dr. Linda Malkas on Targeted Chemotherapy for Solid Tumors**
**Interviewer:** Thank you for joining us today, Dr. Malkas. Can you tell us about the breakthrough in cancer treatment that your team achieved with the AOH1996 molecule?
**Dr. Malkas:** Thank you for having me! We are excited about our recent advances with AOH1996, a novel targeted chemotherapy that selectively annihilates solid tumors. This drug specifically targets a mutated version of the PCNA protein, which plays a critical role in DNA replication and tumor growth, making it a key player in cancer cell proliferation.
**Interviewer:** How does AOH1996 work in the body to combat cancer?
**Dr. Malkas:** Think of PCNA as an airport terminal for cancer cells, with AOH1996 acting like a blizzard that interferes with the operations. When we disrupt this ‘hub’, we effectively halt the flow of resources that cancer cells rely on, which leads to their selective death while sparing healthy cells.
**Interviewer:** That sounds promising! In which types of cancer has your drug shown effectiveness during clinical research?
**Dr. Malkas:** AOH1996 has shown potential in treating various cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We tested it across more than 70 different cancer cell lines, and the results were quite significant.
**Interviewer:** What are the next steps for this research?
**Dr. Malkas:** The next phase involves advancing into human clinical trials. Our team is focused on confirming the efficacy and safety of AOH1996 in patients, which is an essential step in bringing this treatment to those who need it most.
**Interviewer:** It’s amazing to see innovative approaches to treatment emerging. What further implications do you foresee for targeted chemotherapy in the future of cancer treatment?
**Dr. Malkas:** Targeted therapies like AOH1996 represent a shift towards more personalized and effective cancer treatments. By focusing on the unique characteristics of cancer cells, we hope to improve outcomes and reduce collateral damage to healthy tissues. This is a promising direction in oncology, and we are proud to contribute to it.
**Interviewer:** Thank you for sharing your insights, Dr. Malkas. Best of luck with the upcoming trials!
**Dr. Malkas:** Thank you! I’m excited to share more progress with you soon.
